Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients

Diabetologia

Volumn 59, Issue 12, 2016, Pages 2552-2560

  Popovic, Milica ^a   Blum, Claudine A ^a,b   Nigro, Nicole ^a   Mueller, Beat ^b   Schuetz, Philipp ^b   Christ Crain, Mirjam ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Community acquired pneumonia; Corticosteroids; Diabetes mellitus; Hyperglycaemia; Pneumonia; Prednisone; Time to clinical stability

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SWITZERLAND; TERTIARY CARE CENTER; TREATMENT DURATION; BLOOD; COMMUNITY ACQUIRED INFECTION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PNEUMONIA; PREDNISONE; TREATMENT OUTCOME;

EID: 84986277879     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4091-4     Document Type: Article

References (30)

1. Lepper PM, Ott S, Nüesch E et al (2012) Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 344:e3397
2. Yende S, van der Poll T, Lee M (2010) The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 65:870–877
3. Falguera M, Pifarre R (2005) Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 128:3233–3239
4. Fine M, Smith M, Carson C (1996) Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 275:134–141
5. Kornum J, Thomsen R, Riis A (2007) Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 30:2251–2257
6. Saibal M, Rahman S (2013) Community acquired pneumonia in diabetic and non-diabetic hospitalized patients: presentation, causative pathogens and outcome. Bangladesh Med Res Counc Bull 38:98–103
7. Valdez R, Narayan K (1999) Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health 89:1715–1721
8. Miyashita N, Matsushima T, Oka M (2006) The JRS guidelines for the management of community-acquired pneumonia in adults:an update and new recommendations. Intern Med 45:419–428
9. Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382
10. Hirata Y, Tomioka H, Sekiya R (2013) Association of hyperglycemia on admission and during hospitalization with mortality in diabetic patients admitted for pneumonia. Intern Med 52:2431–2438
11. Bader M, Abouchehade K, Yi Y (2011) Antibiotic administration longer than eight hours after triage and mortality of community-acquired pneumonia in patients with diabetes mellitus. Eur J Clin Microbiol Infect Dis 30:881–886
12. Schuetz P, Friedli N, Grolimund E, Kutz A (2014) Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort. Diabetologia 57:275–284
13. Leibovici L, Yehezkelli Y, Porter A (1996) Influence of diabetes mellitus and glycaemic control on the characteristics and outcome of common infections. Diabet Med 13:457–463
14. Becker T, Moldoveanu A (2007) Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract 78:392–397
15. McAlister F, Majumdar S, Blitz S (2005) The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 28:810–815
16. Meijvis SCA, Hardeman H, Remmelts HHF et al (2011) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 377:2023–2030
17. Blum CA, Nigro N, Briel M et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385:1511–1518
18. Blum C, Nigro N, Winzeler B (2014) Corticosteroid treatment for community-acquired pneumonia-the STEP trial: study protocol for a randomized controlled trial. Trials 15:257
19. Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754
20. Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(suppl 2):S27–S72
21. Fine M, Auble T, Yealy D (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
22. Ali NA, O’Brien JM, Dungan K et al (2008) Glucose variability and mortality in patients with sepsis. Crit Care Med 36:2316–2321
23. Egi M, Bellomo R, Stachowski E et al (2006) Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105:244–252
24. Reynolds R, Labad J, Sears A (2012) Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol 166:861–868
25. Agustí C (2003) Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment. Chest J 123:488
26. Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response. JAMA 313:677
27. Siemieniuk RAC, Meade MO, Alonso-Coello P et al (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia. Ann Intern Med 163:519–528
28. Wan Y-D, Sun T-W, Liu Z-Q et al (2016) Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 149:209–219
29. Busillo JM, Cidlowski JA (2013) The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 24:109–119
30. Garcia-Vidal C, Calbo E, Pascual V et al (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30:951–96